Kimberly-Clark to Acquire Kenvue, Maker of Tylenol, in $48.7 Billion Deal
Kimberly-Clark, the consumer goods giant behind brands like Kleenex and Huggies, announced today it is purchasing Kenvue, the company that owns Tylenol and Listerine, in a cash and stock deal valued at approximately $48.7 billion.
The agreement, announced November 3, 2025, will combine two major players in the consumer health and hygiene space, creating a company with roughly $32 billion in annual revenue. Shareholders of Kimberly-Clark will own approximately 54% of the combined entity, while Kenvue shareholders will hold 46%. The deal comes less than two years after Kenvue was spun off from Johnson & Johnson, a move intended to streamline the pharmaceutical company’s operations. This acquisition represents one of the largest corporate takeovers of the year and signals a consolidation trend within the consumer health industry.
The transaction follows a period of scrutiny for Kenvue, which faced pressure from activist investors and navigated recent, unsubstantiated claims linking Tylenol to autism. Former President Donald Trump and Health Secretary Robert F. Kennedy Jr. publicly questioned the safety of acetaminophen, the active ingredient in Tylenol, prompting Kenvue to defend its product. “Nothing is more important to us than the health and safety of the people who use our products,” Kenvue stated on its website. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism.” You can find more information about acetaminophen safety from the Food and Drug Administration.
Kimberly-Clark Chairman and CEO Mike Hsu will lead the combined company, which will maintain its headquarters in Irving, Texas, while also operating from Kenvue facilities. Both companies anticipate approximately $1.9 billion in cost savings within the first three years following the deal’s completion. Shareholders of both companies must approve the transaction, which is expected to finalize in the second half of 2026. For more on corporate mergers and acquisitions, see Investopedia’s guide.
Officials stated the deal is expected to close in the second half of next year, pending shareholder approval and regulatory reviews.
